GSK Annual Report 2002

Additionally, GlaxoSmithKline markets Priorix, a measles,
mumps and rubella vaccine, Typherix, a vaccine for protection
against typhoid fever, and Varilrix, a vaccine against varicella or
chicken pox.
Oncology and emesis
Zofran is used to prevent nausea and vomiting associated with
chemotherapy and radiotherapy for cancer, and is available in
both oral and injectable forms. It is also approved for use in the
prevention and treatment of post-operative nausea and vomiting.
Hycamtin is a second line treatment both for ovarian cancer and
for small cell lung cancer.
Navelbine is approved as first line treatment of non-small cell lung
cancer in combination with cisplatin or as a single agent.
Cardiovascular
Coreg is an alpha/beta blocker which has been proven to be
effective in treating mild, moderate and severe heart failure.
GlaxoSmithKline has sole marketing rights in the USA.
Arthritis
Relafen is a non-steroidal anti-inflammatory drug for the treatment
of arthritis.
Other
The other category includes the Group’s principal dermatological
products; Betnovate, the higher potency Dermovate and the newer
Cutivate are anti-inflammatory steroid products used to treat skin
diseases such as eczema and psoriasis.
Divested products
In accordance with agreements for regulatory approvals of the
merger between Glaxo Wellcome and SmithKline Beecham, the
products Kytril, for the treatment of chemotherapy – and
radiotherapy–induced nausea and vomiting, and Famvir, an
anti-viral for the treatment of shingles and herpes, were divested
in December 2000.
Products – Consumer Healthcare
GlaxoSmithKline’s principal consumer healthcare products are
presently directed to three major areas. An analysis of sales by
these areas is set out below:
2002 2001 2000
£m £m £m
Over-the-counter medicines 1,586 1,603 1,454
Oral care 1,052 1,106 642
Nutritional healthcare 579 575 535
Divested products – – 19
3,217 3,284 2,650
At constant exchange rates 2002 sales were two per cent higher
than 2001.
The major products are:
Description of business GlaxoSmithKline 09
Category Product
Over-the-counter medicines
Analgesics Panadol
Dermatologicals Oxy
Zovirax
Abreva
Gastro-intestinal Tums
Citrucel
Respiratory tract Contac
Beechams
Smoking control Commit
Nicorette
NicoDerm CQ
NiQuitin CQ
Nicabate CQ
Natural wellness support Abtei
Oral care Aquafresh
Corega
Dr Best
Macleans
Odol
Polident
Poligrip
Sensodyne
Nutritional healthcare Horlicks
Lucozade
Ribena
Over-the-counter medicines
The leading products are Panadol, a widely available
paracetamol/acetominophen analgesic; Nicorette gum; the
Nicoderm, NiQuitin CQ and Nicabate range of smoking control
patches; Tums, a calcium based antacid; Citrucel laxative; Contac
for the treatment of colds and influenza; Abtei, a natural
medicines and vitamin range; Oxy acne treatment and Zovirax
and Abreva for the treatment of cold sores.
In 2002, GlaxoSmithKline Consumer Healthcare introduced two
new prescription to over-the-counter switches:
• Eumovate, a cream for clearing the skin flare-up from
dermatitis and eczema in the UK
• Beconase Allergy 24 hours for hayfever in Australia.
Oral care
The leading oral care products are toothpastes and mouthwashes
under the Aquafresh, Sensodyne, Macleans and Odol brand
names, and a range of toothbrushes sold under the Aquafresh,
Sensodyne and Dr Best names. In addition, denture care products
are available principally under the Polident, Poligrip and Corega
brand names.
Nutritional healthcare
The leading products in this category are Lucozade glucose
energy and sports drinks, Ribena blackcurrant-based juice drink
rich in vitamin C, and Horlicks, a range of milk-based malted
food and chocolate drinks.